<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04313608</url>
  </required_header>
  <id_info>
    <org_study_id>GO41943</org_study_id>
    <nct_id>NCT04313608</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma</brief_title>
  <official_title>A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and efficacy of glofitamab or mosunetuzumab in
      combination with gemcitabine and oxaliplatin (Glofit-GemOx or Mosun-GemOx) in participants
      with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell
      lymphoma (HGBCL).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2020</start_date>
  <completion_date type="Anticipated">March 6, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 6, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 17 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of Study Treatment as Measured by Dose Interruptions, Dose Reductions, Dose Intensity, and Treatment Discontinuation due to AEs</measure>
    <time_frame>Up to 17 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) Based on PET/CT as Determined by the Investigator According to the 2014 Lugano Response Criteria</measure>
    <time_frame>Up to 17 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR), Defined as the Proportion of Participants with a Best Overall Response of Partial Response (PR) or CR, as Determined by the Investigator According to the 2014 Lugano Response Criteria</measure>
    <time_frame>Up to 17 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Serum Concentration (Cmin) of the CD20-CD3 Bispecific Antibody</measure>
    <time_frame>At pre-defined intervals from baseline up to 17 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of the CD20-CD3 Bispecific Antibody</measure>
    <time_frame>At pre-defined intervals from baseline up to 17 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve (AUC) of the CD20-CD3 Bispecific Antibody</measure>
    <time_frame>At pre-defined intervals from baseline up to 17 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Anti-Drug Antibodies (ADAs) to Glofitamab</measure>
    <time_frame>Baseline up to 17 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with ADAs to Mosunetuzumab</measure>
    <time_frame>Baseline up to 17 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A: Glofit-GemOx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive up to 8 cycles of Glofit-GemOx (glofitamab in combination with gemcitabine and oxaliplatin) administered in 21-day cycles, followed by up to 4 cycles of glofitamab monotherapy. A single dose of obinutuzumab will be administered 7 days prior to the first dose of glofitamab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Mosun-GemOx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive up to 8 cycles of Mosun-GemOx (mosunetuzumab in combination with gemcitabine and oxaliplatin) administered in 21-day cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glofitamab</intervention_name>
    <description>Participants will receive intravenous (IV) glofitamab in combination with gemcitabine and oxaliplatin for up to 8 cycles, followed by up to 4 cycles of glofitamab monotherapy.</description>
    <arm_group_label>Arm A: Glofit-GemOx</arm_group_label>
    <other_name>RO7082859</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.</description>
    <arm_group_label>Arm A: Glofit-GemOx</arm_group_label>
    <arm_group_label>Arm B: Mosun-GemOx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.</description>
    <arm_group_label>Arm A: Glofit-GemOx</arm_group_label>
    <arm_group_label>Arm B: Mosun-GemOx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mosunetuzumab</intervention_name>
    <description>Participants will receive IV mosunetuzumab in combination with gemcitabine and oxaliplatin for up to 8 cycles.</description>
    <arm_group_label>Arm B: Mosun-GemOx</arm_group_label>
    <other_name>RO7030816</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Participants will receive a single dose of IV obinutuzumab 7 days prior to the first administration of glofitamab.</description>
    <arm_group_label>Arm A: Glofit-GemOx</arm_group_label>
    <other_name>RO5072759</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).</description>
    <arm_group_label>Arm A: Glofit-GemOx</arm_group_label>
    <arm_group_label>Arm B: Mosun-GemOx</arm_group_label>
    <other_name>RO4877533</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2

          -  Histologically confirmed B-cell lymphoma, including one of the following diagnoses per
             the 2016 World Health Organization (WHO) classification of lymphoid neoplasms: DLBCL,
             not otherwise specified (NOS); HGBCL with MYC and BCL2 and/or BCL6 rearrangements;
             HGBCL, NOS

          -  R/R disease, defined as follows: Relapse: disease that has recurred following a
             response that lasted &gt;/=6 months after completion of last line of therapy; Refractory:
             disease that progressed during therapy or progressed within 6 months (&lt;6 months) of
             prior therapy

          -  At least one line of prior systemic therapy

          -  At least one bi-dimensionally measurable nodal lesion or one bi-dimensionally
             measurable extranodal lesion, as measured on positron emission tomography-computed
             tomography (PET/CT) scan

          -  Adequate hematologic function

          -  For women of childbearing potential: agreement to remain abstinent (refrain from
             heterosexual intercourse) or use contraceptive methods, and agreement to refrain from
             donating eggs, as follows: Women must remain abstinent or use contraceptive methods
             with a failure rate of &lt;1% per year during the treatment period and for at least 18
             months after the final dose of obinutuzumab, 6 months after the final dose of
             gemcitabine, 9 months after the final dose of oxaliplatin, 3 months after the final
             dose of mosunetuzumab, 3 months after the final dose of tocilizumab, and 2 months
             after the final dose of glofitamab. Women must refrain from donating eggs during this
             same period

          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
             contraceptive methods, and agreement to refrain from donating sperm, as follows: With
             a female partner of childbearing potential or pregnant female partners, men must
             remain abstinent or use a condom plus an additional contraceptive method that together
             result in a failure rate of &lt;1% per year during the treatment period and for at least
             2 months after the final dose of glofitamab, 2 months after the final dose of
             mosunetuzumab, 2 months after the final dose of tocilizumab (if applicable), 3 months
             after the final dose of obinutuzumab, and 6 months after the final dose of oxaliplatin
             or gemcitabine to avoid exposing the embryo. Men must refrain from donating sperm
             during this same period.

        Exclusion Criteria

          -  Participant has failed only one prior line of therapy and is a candidate for stem cell
             transplantation

          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
             antibodies (or recombinant antibody-related fusion proteins) or known sensitivity or
             allergy to murine products

          -  Contraindication to obinutuzumab, gemcitabine, oxaliplatin, or tocilizumab

          -  Prior treatment with a bispecific antibody targeting both CD20 and CD3, including
             glofitamab and mosunetuzumab

          -  Grade &gt;1 peripheral neuropathy

          -  Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy,
             or any investigational agent for the purposes of treating cancer within 2 weeks prior
             to first study treatment

          -  Treatment with monoclonal antibodies for the purposes of treating cancer within 4
             weeks prior to the first study treatment

          -  Primary or secondary central nervous system (CNS) lymphoma at the time of recruitment
             or history of CNS lymphoma

          -  Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or
             neurodegenerative disease

          -  History of other malignancy that could affect compliance with the protocol or
             interpretation of results

          -  Evidence of significant, uncontrolled concomitant diseases that could affect
             compliance with the protocol or interpretation of results, including significant
             cardiovascular disease (such as New York Heart Association Class III or IV cardiac
             disease, myocardial infarction within the last 6 months, unstable arrhythmias, or
             unstable angina) or significant pulmonary disease (including obstructive pulmonary
             disease and history of bronchospasm)

          -  Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection
             (excluding fungal infections of nail beds) at study enrollment or any major episode of
             infection (as evaluated by the investigator) within 4 weeks prior to first study
             treatment

          -  Suspected or latent tuberculosis

          -  Positive test results for chronic hepatitis B virus (HBV) infection

          -  Positive test results for hepatitis C virus (HCV) antibody

          -  Known HIV-seropositive status

          -  Known or suspected chronic active Epstein-Barr virus infection

          -  Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)

          -  History of progressive multifocal leukoencephalopathy

          -  Adverse events from prior anti-cancer therapy that have not resolved to Grade 1 or
             better (with the exception of alopecia and anorexia)

          -  Administration of a live, attenuated vaccine within 4 weeks prior to the first study
             treatment administration or anticipation that such a live, attenuated vaccine will be
             required during the study

          -  Prior solid organ transplantation

          -  Prior allogenic stem cell transplant

          -  Active autoimmune disease requiring treatment

          -  Prior treatment with systemic immunosuppressive medications (including, but not
             limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor
             necrosis factor agents) within 4 weeks prior to the first dose of study treatment

          -  Corticosteroid therapy within 2 weeks prior to first dose of study treatment, with
             exceptions defined by the study protocol

          -  Recent major surgery (within 4 weeks before the first study treatment) other than for
             diagnosis

          -  Clinically significant history of liver disease, including cirrhosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO41943 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prince of Wales Hospital; Haematology</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Health Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

